A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

Summary

This open-label, single arm study will evaluate the tolerability and efficacy of Valcyte (valganciclovir) in the prevention of cytomegalovirus disease in pediatric renal transplant recipients. After transplantation, patients (aged 4 months to 16 years) will receive Valcyte orally daily for up to 200 days post-transplant and will be followed for 52 weeks post-transplantation.

Timeline

Start

2011-07-31

Primary completion

2013-05-31

Completion

2013-05-31

Drugs

Indications